title: Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients.
abstract: Hemophagocytic syndrome (HPS) is a potentially life-threatening complication of systemic inflammatory disorders. Adult-onset Still disease (AOSD) is one of the systemic autoimmune diseases associated with reactive hemophagocytic syndrome (RHS). This study aimed to evaluate the characteristic findings, predictive factors, and prognosis of RHS in patients with AOSD. We retrospectively evaluated 109 patients diagnosed with AOSD and reviewed their clinical data and laboratory findings, including the biopsy results of 21 AOSD patients with RHS. Moreover, data from 17 hemophagocytic lymphohistiocytosis (HLH) patients evaluated during the same period were compared with those from the RHS patients. Twenty-one patients (19.3%) developed RHS during the course of AOSD, and only 7 patients (6.4%) were confirmed by bone marrow, liver, or lymph node biopsy. AOSD patients with RHS showed significantly higher frequencies of splenomegaly, hepatomegaly, and lymphadenopathy than did those without RHS. Moreover, patients with RHS showed significantly higher relapse rates than those without RHS (61.9% vs 18.2%, P < 0.001). Possible triggering factors inducing hemophagocytosis were detected in 16 of 21 RHS patients (76.2%): disease flare in 12 patients (75%), infection in 3 patients (18.8%), and drug use in 1 patient (6.3%). AOSD patients with RHS showed higher frequencies of leukopenia, anemia, thrombocytopenia, hypoalbuminemia, hypofibrinogenemia, hypertriglyceridemia, hyperferritinemia, and elevated lactate dehydrogenase levels than did those without RHS. Multivariate logistic regression with forward selection procedure showed that low platelet count (<121,000/mm³), anemia, and hepatomegaly were independent predictors of RHS. Patients with definite RHS and those with probable RHS showed comparable results. Although RHS is a life-threatening complication of AOSD, long-term prognosis was observed to be similar in patients with and those without RHS. Compared to RHS patients, HLH patients had poor prognosis, such as higher death rates (52.9% vs 9.5%, P = 0.005). RHS can be considered when an AOSD patient shows at least 2 of the following 3 findings: low platelet count, anemia, and hepatomegaly. Diagnostic confirmation by biopsy may not be essential if typical clinical findings of RHS are present. Moreover, prognosis of RHS was better than that of HLH diagnosed by the presence of trilineage cytopenia at admission.
authors: From the Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
authors: Chang-Bum
authors: CB
authors: Bae
authors: Ju-Yang
authors: JY
authors: Jung
authors: Hyoun-Ah
authors: HA
authors: Kim
authors: Chang-Hee
authors: CH
authors: Suh
mesh_terms: D000328:Adult; D000347:Afibrinogenemia / Q000150:complications; D000740:Anemia / Q000150:complications; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D005260:Female; D005293:Ferritins / Q000097:blood; D006529:Hepatomegaly / Q000209:etiology; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications; D034141:Hypoalbuminemia / Q000150:complications; D007239:Infections / Q000150:complications; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008206:Lymphatic Diseases / Q000209:etiology; D051359:Lymphohistiocytosis, Hemophagocytic / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D013163:Splenomegaly / Q000209:etiology; D016706:Still's Disease, Adult-Onset / Q000097:blood / Q000150:complications* / Q000401:mortality; D013921:Thrombocytopenia / Q000150:complications
chemical_list: D000900:Anti-Bacterial Agents; D005293:Ferritins; D007770:L-Lactate Dehydrogenase
references: Arthritis Rheum. 2009 Nov;60(11):3388-99
references: 19877067
references: Curr Opin Hematol. 2008 Jul;15(4):359-67
references: 18536575
references: Med Sci Monit. 2008 Mar;14(3):RA27-36
references: 18301366
references: Rheumatology (Oxford). 2003 Feb;42(2):375-9
references: 12595640
references: Clin Exp Rheumatol. 2005 Jan-Feb;23(1):100-2
references: 15789896
references: Pediatr Pathol. 1992 Jan-Feb;12(1):51-66
references: 1348582
references: Blood Rev. 2007 Sep;21(5):245-53
references: 17590250
references: Rheumatology (Oxford). 2008 Nov;47(11):1686-91
references: 18782855
references: Pediatr Blood Cancer. 2008 Feb;50(2):192-4
references: 18061932
references: Arthritis Res Ther. 2005;7(1):R30-7
references: 15642140
references: Arch Dis Child. 2001 Nov;85(5):421-6
references: 11668110
references: Pediatr Crit Care Med. 2009 May;10(3):387-92
references: 19325510
references: Int J Hematol. 1997 Aug;66(2):135-51
references: 9277044
references: Br J Haematol. 2004 Jan;124(1):4-14
references: 14675403
references: Rheumatol Int. 2009 Jun;29(8):973-4
references: 19115058
references: J Rheumatol. 2003 May;30(5):1027-8
references: 12734900
references: Clin Rheumatol. 2012 Aug;31(8):1223-30
references: 22615046
references: Curr Opin Rheumatol. 2002 Sep;14(5):548-52
references: 12192253
references: Mod Rheumatol. 2008;18(1):72-5
references: 18161002
references: Pediatr Blood Cancer. 2007 Feb;48(2):124-31
references: 16937360
references: Clin Rheumatol. 2007 May;26(5):797-800
references: 16550302
references: Curr Opin Rheumatol. 2003 Sep;15(5):587-90
references: 12960485
references: Autoimmun Rev. 2004 Feb;3(2):69-75
references: 15003190
references: Curr Opin Rheumatol. 2012 Jan;24(1):113-8
references: 22089101
references: Medicine (Baltimore). 1991 Mar;70(2):118-36
references: 2005777
references: Rheumatol Int. 2012 Oct;32(10):3269-72
references: 20383508
references: Mod Rheumatol. 2004;14(3):205-15
references: 17143676
references: Ann Rheum Dis. 2006 Dec;65(12):1596-601
references: 16540551
references: Lancet. 2014 Apr 26;383(9927):1503-1516
references: 24290661
references: Arthritis Rheum. 2004 Mar;50(3):689-98
references: 15022306
references: Arthritis Rheum. 2003 Oct 15;49(5):633-9
references: 14558048
references: Medicine (Baltimore). 2010 Jan;89(1):37-46
references: 20075703
references: Am J Hematol. 2001 Sep;68(1):4-10
references: 11559930
references: Int J Rheum Dis. 2012 Aug;15(4):e60-2
references: 22898226
references: Am J Hematol. 2006 Jan;81(1):59-61
references: 16369976
references: J Rheumatol. 1992 Mar;19(3):424-30
references: 1578458
references: Rheumatology (Oxford). 2001 Nov;40(11):1285-92
references: 11709613
references: J Leukoc Biol. 2003 Feb;73(2):209-12
references: 12554797